Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Alcoholism, Clinical and Experimental Research|May 18, 2016
Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications DevelopmentRaye Z Litten, Daniel E Falk, Megan L Ryan, et al.Substance Abuse|March 2, 2016
Potential medications for the treatment of alcohol use disorder: An evaluation of clinical efficacy and safetyRaye Z Litten, Bonnie B Wilford, Daniel E Falk, et al.Contemporary Clinical Trials|August 14, 2016
An exploratory evaluation of Take Control: A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorderEric G Devine, Megan L Ryan, Daniel E Falk, et al.Addiction Biology|March 31, 2012
Medications development to treat alcohol dependence: a vision for the next decadeRaye Z Litten, Mark Egli, Markus Heilig, et al.Alcoholism, Clinical and Experimental Research|May 5, 2020
Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment-Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double-Blind, Placebo-Controlled Clinical Trial of VareniclineRobert Miranda, Stephanie S O'Malley, Hayley Treloar Padovano, et al.Alcoholism, Clinical and Experimental Research|September 29, 2011
A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patientsRaye Z Litten, Joanne B Fertig, Daniel E Falk, et al.Journal of Addiction Medicine|June 4, 2013
A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependenceRaye Z Litten, Megan L Ryan, Joanne B Fertig, et al.Alcoholism, Clinical and Experimental Research|February 14, 2012
A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patientsJoanne B Fertig, Megan L Ryan, Daniel E Falk, et al.Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 24, 2016
A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol DependenceMegan L Ryan, Daniel E Falk, Joanne B Fertig, et al.Alcoholism, Clinical and Experimental Research|November 8, 2018
Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and SafetyDaniel E Falk, Megan L Ryan, Joanne B Fertig, et al.Pageof 1